UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 94

Sortiert nach

Increased immune infiltration and chemokine receptor expression in head and neck epithelial tumors after neoadjuvant immunotherapy with the IRX-2 regimen

Oncoimmunology, 2018-05, Vol.7 (5), p.e1423173-e1423173

2018

Volltextzugriff (PDF)

First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients

Journal of translational medicine, 2012-08, Vol.10 (1), p.156-156, Article 156

2012

Volltextzugriff (PDF)

The Gene Associated with Trichorhinophalangeal Syndrome in Humans Is Overexpressed in Breast Cancer

Proceedings of the National Academy of Sciences - PNAS, 2005-08, Vol.102 (31), p.11005-11010

2005

Volltextzugriff (PDF)

Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide

Journal for immunotherapy of cancer, 2016-10, Vol.4 (1), p.68-68, Article 68

2016

Volltextzugriff (PDF)

Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer

Clinical cancer research, 2008-08, Vol.14 (15), p.4843-4849

2008

Volltextzugriff (PDF)

Serum‐derived carcinoembryonic antigen (CEA) activates fibroblasts to induce a local re‐modeling of the extracellular matrix that favors the engraftment of CEA‐expressing tumor cells

International journal of cancer, 2018-10, Vol.143 (8), p.1963-1977

2018

Volltextzugriff (PDF)

Enhancing cancer vaccines with immunomodulators

Vaccine, 2007-09, Vol.25, p.B72-B88

Berinstein, Neil L

2007

Volltextzugriff (PDF)

PD‐L1 expression predicts efficacy in the phase II SPiReL trial with MVP‐S, pembrolizumab, and low‐dose CPA in R/R DLBCL

European journal of haematology, 2023-08, Vol.111 (2), p.191-200

2023

Volltextzugriff (PDF)

Featured Cover

European journal of haematology, 2023-08, Vol.111 (2), p.i-i

2023

Volltextzugriff (PDF)

Peptide Based Vaccine Approaches for Cancer-A Novel Approach Using a WT-1 Synthetic Long Peptide and the IRX-2 Immunomodulatory Regimen

Cancers, 2011-10, Vol.3 (4), p.3991-4009

2011

Volltextzugriff (PDF)

Therapeutic vaccines and cancer : focus on DPX-0907

Biologics, 2014-01, Vol.8 (default), p.27-38

2014

Volltextzugriff (PDF)

Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma

Journal of clinical oncology, 2014-06, Vol.32 (17), p.1797-1803

2014

Volltextzugriff (PDF)

Strategies to Enhance the Therapeutic Activity of Cancer Vaccines: Using Melanoma as a Model

Annals of the New York Academy of Sciences, 2009-09, Vol.1174 (1), p.107-117

Berinstein, Neil L.

2009

Volltextzugriff (PDF)

Abstract 4903: Multimodal therapy with a potent vaccine, metronomic cyclophosphamide and anti-PD-1 enhances immunotherapy of advanced tumors by increasing activation and clonal expansion of tumor infiltrating T cells

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.4903-4903

2016

Volltextzugriff (PDF)

Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients

Oncoimmunology, 2015-08, Vol.4 (8), p.e1026529-e1026529

2015

Volltextzugriff (PDF)

Chronic Lymphocytic Leukemia-reactive T Cells during Disease Progression and after Autologous Tumor Cell Vaccines

Clinical cancer research, 2003-05, Vol.9 (5), p.1656-1665

2003

Volltextzugriff (PDF)

Survival of patients with transformed lymphoma in the rituximab era

Annals of hematology, 2014-06, Vol.93 (6), p.1007-1014

2014

Volltextzugriff (PDF)

Lack of prognostic value of FCGR3A-V158F polymorphism in non-Hodgkin's lymphoma

Haematologica (Roma), 2008-08, Vol.93 (8), p.1265-1267

2008

Volltextzugriff (PDF)

Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells

Journal of interferon & cytokine research, 2016-05, Vol.36 (5), p.291

2016

Volltextzugriff (PDF)

IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers

OncoTargets and therapy, 2018-01, Vol.11, p.3731-3746

2018

Volltextzugriff (PDF)

Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response

Oncoimmunology, 2014, Vol.3 (8), p.e953407-e953407

2014

Volltextzugriff (PDF)

Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen

Cancer Immunology, Immunotherapy, 2012-06, Vol.61 (6), p.771-782

2012

Volltextzugriff (PDF)

Management of newly diagnosed high‐risk and intermediate‐risk follicular lymphoma with 90Y ibritumomab tiuxetan in a phase II study

Hematological oncology, 2018-08, Vol.36 (3), p.525-532

2018

Volltextzugriff (PDF)

Management of newly diagnosed high-risk and intermediate-risk follicular lymphoma with 90 Y ibritumomab tiuxetan in a phase II study

Hematological oncology, 2018-04, Vol.36 (3), p.525-532

2018

Volltextzugriff (PDF)

A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma

Cancer Immunology, Immunotherapy, 2012-06, Vol.61 (6), p.783-788

2012

Volltextzugriff (PDF)

1 – 25 von 94

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(87)
Mit Volltextzugriff
(78)

Publikationsform

Artikel
(90)
Buchkapitel
(4)

Sprache

Englisch
(94)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Increased immune infiltration and chemokine receptor expression in head and neck epithelial tumors after neoadjuvant immunotherapy with the IRX-2 regimen

First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients

The Gene Associated with Trichorhinophalangeal Syndrome in Humans Is Overexpressed in Breast Cancer

Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide

Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer

Serum‐derived carcinoembryonic antigen (CEA) activates fibroblasts to induce a local re‐modeling of the extracellular matrix that favors the engraftment of CEA‐expressing tumor cells

Enhancing cancer vaccines with immunomodulators

PD‐L1 expression predicts efficacy in the phase II SPiReL trial with MVP‐S, pembrolizumab, and low‐dose CPA in R/R DLBCL

Featured Cover

Peptide Based Vaccine Approaches for Cancer-A Novel Approach Using a WT-1 Synthetic Long Peptide and the IRX-2 Immunomodulatory Regimen

Therapeutic vaccines and cancer : focus on DPX-0907

Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma

Strategies to Enhance the Therapeutic Activity of Cancer Vaccines: Using Melanoma as a Model

Abstract 4903: Multimodal therapy with a potent vaccine, metronomic cyclophosphamide and anti-PD-1 enhances immunotherapy of advanced tumors by increasing activation and clonal expansion of tumor infiltrating T cells

Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients

Chronic Lymphocytic Leukemia-reactive T Cells during Disease Progression and after Autologous Tumor Cell Vaccines

Survival of patients with transformed lymphoma in the rituximab era

Lack of prognostic value of FCGR3A-V158F polymorphism in non-Hodgkin's lymphoma

Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells

IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers

Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response

Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen

Management of newly diagnosed high‐risk and intermediate‐risk follicular lymphoma with 90Y ibritumomab tiuxetan in a phase II study

Management of newly diagnosed high-risk and intermediate-risk follicular lymphoma with 90 Y ibritumomab tiuxetan in a phase II study

A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma

Suchergebnisse filtern